Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.40 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.40 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.40 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700361 | 0.98 | CD44 (0.49) | CD44KDM4EHPGDHSD17B10KEAP1 | |
| Hydrochloric Acid SCHEMBL4511906 | 0.88 | PNMT (0.47) | KDM4EHPGDHSD17B10KEAP1NFE2L2 | |
| SCHEMBL13678711 | 0.87 | PNMT (0.49) | CD44KDM4EHPGDHSD17B10KEAP1 | |
| Hydrochloric Acid SCHEMBL6765523 | 0.86 | KDM4E (0.45) | KDM4EHPGDHSD17B10KEAP1NFE2L2 | |
| SCHEMBL20782838 | 0.84 | CD44 (0.53) | CD44KDM4EALDH1A1PNMTNMT1 | |
| Hydrochloric Acid SCHEMBL10356561 | 0.82 | HTR6 (0.56) | CD44KDM4EALDH1A1PNMT | |
| Hydrochloric Acid SCHEMBL2867007 | 0.80 | CD44 (0.54) | CD44PNMTMAOBP2RX7 | |
| SCHEMBL2810333 | 0.78 | CD44 (0.56) | CD44PNMTMAOBP2RX7 | |
| Hydrochloric Acid SCHEMBL9959608 | 0.78 | ALDH1A1 (0.44) | CD44KDM4EALDH1A1PNMTNMT1 | |
| Hydrochloric Acid SCHEMBL9959613 | 0.77 | HTR6 (0.47) | ALDH1A1PNMTPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143021-B1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER (US) | 2019-06-12 | — | — | EP | disclosed |
| US-7026479-B2 | Process for the production of quinazolines | BOULTON LEE TERENCE | 2006-04-11 | — | — | US | disclosed |
| EP-1387839-B1 | PROCESS FOR THE PRODUCTION OF QUINAZOLINES | PFIZER LTD (GB) | 2006-03-08 | — | — | EP | disclosed |
| US-20040158062-A1 | Process for the production of quinazolines | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| US-6734303-B2 | THERAPY FOR BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2004-05-11 | — | — | US | disclosed |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC | 2004-02-19 | — | — | US | disclosed |
| US-6683085-B2 | 4-AMINO-6,7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1,2,3,4 -TETRAHYDROISOQUINOL-2-YL)-5-(2-PYRIDYL)QUINAZOLINE MESYLATE; FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2004-01-27 | — | — | US | disclosed |
| EP-0887344-B1 | Quinolines and quinazolines useful in therapy | PFIZER LTD (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-6649620-B2 | Particularly in the treatment of benign prostatic hyperplasia. | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-20020010188-A1 | 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 -tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate; for treatment of benign prostatic hyperplasia | BASFORD PATRICIA ANN (GB) | 2002-01-24 | — | — | US | disclosed |
| WO-2001064672-A1 | 4-AMINO-6,7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1,2,3,4-TETRAHYDROISOQUINOL-2-YL)-5-(2-PYRIDYL)QUINAZOLINE MESYLAT AND POLYMORPHS | PFIZER LIMITED (GB) | 2001-09-07 | — | — | WO | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| US-6048864-A | Quinolines and quinazolines useful in therapy | PFIZER INC (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| EP-0887344-A1 | Quinolines and quinazolines useful in therapy | Pfizer Limited (GB) | 1998-12-30 | — | — | EP | disclosed |
| EP-0875506-A1 | Quinoline and quinazoline compounds useful in therapy | Pfizer Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | NR3C1 2133/4885ADRA1A 100/4885MAOB 262/4885 |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, SDHA | NR3C1 1484/4885ADRA1A 108/4885MAOB 160/4885 |
| US-20040158062-A1 | Process for the production of quinazolines | BPHL, QDPR, NQO2 | NR3C1 4820/4885ADRA1A 665/4885MAOB 289/4885 |
| US-20020010188-A1 | 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 -tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate; for treatment of benign prostatic hyperplasia | BPHL, QDPR, DPYD | NR3C1 3623/4885ADRA1A 301/4885MAOB 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.